|
|
|
|
|
|
|
|
|
|
|
04.11.25 - 12:54
|
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) (Business Wire)
|
|
|
Strategic financing to advance development of sac-TMT while Merck continues to progress its broad and expansive pipeline
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (“Blackstone”) for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2), a protein found on the surface of various cancer cells. Merck is currently evaluating sac-TMT in 15 global Phase 3 clinical trials spanning six tumor types, including breast, endometrial and lung cancers.
“This agreement positions Merck to harness the potential of sac-TMT, a promising ADC candidate targeting TROP2, while we continue to advance our broad and expansive pipeline,” said Caroline Litchfield, chief financial officer, Merck. “We are making important investments to drive patient ...
|
|
|
31.10.25 - 09:45
|
Merck-Aktie: Darum ist sie besser als der Kurs es zeigt! (Sharedeals)
|
|
|
Die erste Kursreaktion nach den Quartalszahlen des Pharmakonzern Merck & Co. fiel negativ aus. Doch besitzt das Unternehmen Wachstumstreiber, deren Wert es anzuerkennen gilt. Quartalszahlen über Erwartungen Merck meldete für das dritte Quartal einen Umsatz von 17,3 Milliarden US-Dollar, ein Plus von 9,4 Prozent gegenüber dem Vorquartal. Treiber waren vor allem das Segment Animal Health […]
The post Merck-Aktie: Darum ist sie besser als der Kurs es zeigt! first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.10.25 - 12:12
|
ROUNDUP: Merck Boosts FY25 Adj. EPS Outlook (AFX)
|
|
|
KENILWORTH (NJ) (dpa-AFX) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, raised......
|
|
|
|
|
|
|
30.10.25 - 11:36
|
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results (Business Wire)
|
|
|
Total Worldwide Sales Were $17.3 Billion, an Increase of 4% From Third Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 3%
KEYTRUDA Sales Grew 10% to $8.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 8%
WINREVAIR Sales Were $360 Million; Growth of 141% Both Nominally and Excluding the Impact of Foreign Exchange
CAPVAXIVE Sales Were $244 Million
GARDASIL/GARDASIL 9 Sales Declined 24% to $1.7 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 25%
Animal Health Sales Grew 9% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 7%
GAAP EPS Was $2.32; Non-GAAP EPS Was $2.58; GAAP and Non-GAAP EPS Include a Charge of $0.10 per Share for Milestone Payment to LaNova for Technology Transfer for MK-2010
Received FDA Approval of KEYTRUDA QLEX Injection for Subcutaneous Use Across All Solid Tumor Indications for KEYTRUDA
Presented New Research Across More Than 20 Types of Cancer and Multiple Treatment Settings at ESMO Congress 2025, Including Positive...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
